Below are answers to some of the most common questions patients ask regarding our specialized in-office therapies and advanced clinical treatments. These FAQs cover chronic dry eye diagnostics, Intense Pulsed Light (IPL) and Radiofrequency (RF) procedures via the Envision by InMode platform, and evidence-based childhood myopia control protocols including Ortho-K, MiSight® lenses, and low-dose Atropine drops.
If you are seeking targeted treatment for persistent dry eyes or proactive vision care for your child, you can learn more about our Advanced Specialty Services to explore our cutting-edge diagnostic technology, custom treatment plans, and long-term care management.
The leading root cause of chronic dry eye is Meibomian Gland Dysfunction (MGD), accounting for up to 86% of all cases. MGD occurs when the tiny oil-producing glands in the eyelids become clogged, preventing healthy lipids from sealing the tear film and causing tears to evaporate rapidly. A therapeutic optometrist specializing in dry eye disease is best qualified to diagnose and treat it.
Chronic dry eye syndrome is a progressive, non-curable condition that rarely disappears on its own without targeted intervention. However, while it cannot be permanently cured, its symptoms can be successfully managed and controlled long-term through advanced therapies that restore natural gland function.
Triggers include prolonged digital screen use (which reduces blink rates), low-humidity air conditioning or heating, contact lens overwear, ocular rosacea, hormonal shifts (such as menopause), systemic health conditions (like Sjögren’s syndrome or thyroid disorders), and certain medications (including antihistamines, decongestants, and blood pressure therapies).
Over-the-counter artificial tears only provide temporary, surface-level lubrication. They do not unblock clogged meibomian glands, repair inflamed eyelid tissue, or address the underlying vascular causes of evaporative dry eye, requiring frequent reapplication without fixing the core problem.
A thorough dry eye evaluation utilizes advanced diagnostics, including:
When at-home maintenance fails, in-office procedural options include thermal gland expression, punctal plug insertion (to retain tears), amniotic membrane therapy, and light-and-energy-based procedures such as Intense Pulsed Light (IPL) and Radiofrequency (RF) therapies.
IPL delivers controlled, high-intensity broad-spectrum light pulses to the skin around the lower eyelids and cheeks. The thermal energy shrinks abnormal, telangiectatic blood vessels that leak inflammatory factors into the eyelids, liquefies hardened oils blocking the meibomian glands, and eliminates harmful bacteria and Demodex mites along the lash line.
Yes. Clinical studies and patient outcomes show an 85%+ success rate in achieving significant, long-lasting relief from evaporative dry eye symptoms and Meibomian Gland Dysfunction.
Most patients notice noticeable improvement in eye comfort within 1 to 2 weeks following their second session. A full treatment course typically consists of 4 sessions spaced 3 to 4 weeks apart, followed by a single annual maintenance visit to sustain long-term gland health.
Envision by InMode is an advanced dual-action dry eye treatment system. Combining IPL (Lumecca) with bipolar Radiofrequency (Forma-I) allows the procedure to target inflammation from two angles: IPL targets vascular inflammation and bacterial buildup, while RF delivers gentle thermal energy to deep tissue to melt stubborn gland blockages, stimulate collagen, and improve local blood circulation.
An in-office IPL session takes approximately 30 to 40 minutes. Protective eyewear or shields are applied over the eyes, a cooling gel is placed on the skin, and a handheld handpiece delivers gentle pulses of light to the cheeks and lower eyelids. The procedure is non-invasive and virtually painless, often described as a brief warm snap on the skin.
Arrive with a clean face completely free of makeup, lotions, or sunscreens, and avoid heavy sun exposure, tanning, or topical retinoids for 5 to 7 days prior to treatment. There is zero downtime, you can return to work or normal daily activities immediately, though applying broad-spectrum sunscreen is recommended.
Standard single-vision glasses and contacts only correct central distance vision while allowing peripheral light to focus behind the retina, which actually signals the eye to continue stretching. Myopia management uses specialized optical and pharmacological protocols to alter peripheral focus (peripheral defocus) or biochemical signals, actively slowing down the rate of childhood eye elongation.
Yes. Myopia is a progressive condition where the eyeball grows excessively long (axial elongation). Uncontrolled high myopia drastically increases a child’s lifetime risk of sight-threatening eye conditions in adulthood, including retinal detachment, myopic maculopathy, glaucoma, and early cataracts. Early intervention stops rapid vision decline before permanent structural changes occur.
While myopia cannot be reversed once the eye has lengthened, evidence-based myopia management therapies can slow progression by 50% to 70% on average compared to standard glasses.
Our myopia management program includes four options:
Programs typically begin between ages 6 and 12, during the window of most rapid prescription progression. However, treatment can be tailored for any child demonstrating progressive nearsightedness.
In addition to tracking prescription changes via annual refractions, progress is monitored using axial length measurement (measuring the exact millimeter length of the eye from front to back) and corneal topography mapping during routine 3- to 6-month checkups.